Effective immediately, FDA has changed the labels on two medications used to bring down LDL cholesterol levels: bempedoic acid (Nexletol) and bempedoic acid/ezetimibe (Nexlizet).

FDA gave final approval to required safety labeling updates for opioids. The updates, first included in an April 2023 drug safety communication, include the addition of language stating the risk of overdose increases with higher doses for all opioid analgesics and that immediate-release opioids should not be used for an extended period of time unless a patient’s pain is so severe that it cannot be controlled otherwise.